Guillermo Ocaña-Ramm, Moisés Manuel Gallardo-Pérez, Solón Javier Garcés-Eisele, Daniela Sánchez-Bonilla, Max Robles-Nasta, Edgar Jared Hernández-Flores, Luis Enrique Hamilton-Avilés, Paola Negrete-Rodríguez, Miranda Melgar-de-la-Paz, Olivia Lira-Lara, Juan Carlos Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles
Introduction
Biomarkers that help to evaluate the immune system and could be useful in multiple sclerosis (MS) are the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and systemic immune-inflammatory index (SII). The objective of this work is to evaluate the significance of the SII index, PLR, and NLR before and after transplantation in individuals with MS who underwent autologous hematopoietic stem cell transplant (aHSCT) at a single institution.
Methods
Patients with MS who received an aHSCT between 2017 and 2022 were included in the study. NLR, PLR, and SII index were calculated prior to the transplant and 100 days after, and evaluation of the expanded disability status scale (EDSS) was done before the transplant and 12 months after. The cohort was divided into two groups: aHSCT responders (R) and nonresponders (NR).
Results
Fifty-eight individuals were examined: 37 patients in the responders group R group and 21 in NR group. There was no statistically significant difference in the SII, NLR, and PLR prior to the transplant, however at 100 days post-HSCT, NLR in the R group was 1.8 versus 3.1 in the NR group (p = 0.003), PLR was 194 versus 295, respectively (p = 0.024), meanwhile SII index was 489.5 versus 729.3 (p < 0.001).
Conclusion
High NLR and SII index values after the aHSCT were associated with a worsening in the EDSS score. However, since this is the first ever study that compared NLR and SII index with the aHSCT response in persons with MS, further studies must be performed to corroborate this information.
{"title":"Neutrophil to lymphocyte ratio and systemic immune-inflammatory index as markers of response to autologous hematopoietic stem cell transplantation in persons with multiple sclerosis","authors":"Guillermo Ocaña-Ramm, Moisés Manuel Gallardo-Pérez, Solón Javier Garcés-Eisele, Daniela Sánchez-Bonilla, Max Robles-Nasta, Edgar Jared Hernández-Flores, Luis Enrique Hamilton-Avilés, Paola Negrete-Rodríguez, Miranda Melgar-de-la-Paz, Olivia Lira-Lara, Juan Carlos Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles","doi":"10.1111/ijlh.14259","DOIUrl":"10.1111/ijlh.14259","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Biomarkers that help to evaluate the immune system and could be useful in multiple sclerosis (MS) are the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and systemic immune-inflammatory index (SII). The objective of this work is to evaluate the significance of the SII index, PLR, and NLR before and after transplantation in individuals with MS who underwent autologous hematopoietic stem cell transplant (aHSCT) at a single institution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with MS who received an aHSCT between 2017 and 2022 were included in the study. NLR, PLR, and SII index were calculated prior to the transplant and 100 days after, and evaluation of the expanded disability status scale (EDSS) was done before the transplant and 12 months after. The cohort was divided into two groups: aHSCT responders (R) and nonresponders (NR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-eight individuals were examined: 37 patients in the responders group R group and 21 in NR group. There was no statistically significant difference in the SII, NLR, and PLR prior to the transplant, however at 100 days post-HSCT, NLR in the R group was 1.8 versus 3.1 in the NR group (<i>p</i> = 0.003), PLR was 194 versus 295, respectively (<i>p</i> = 0.024), meanwhile SII index was 489.5 versus 729.3 (<i>p</i> < 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>High NLR and SII index values after the aHSCT were associated with a worsening in the EDSS score. However, since this is the first ever study that compared NLR and SII index with the aHSCT response in persons with MS, further studies must be performed to corroborate this information.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139992186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kim Callebaut, Eva Gijbels, Jonathan Vanbesien, Dries Deeren, Jan Van Droogenbroeck, Jan Emmerechts, Elisabeth Moreau
Objectives
Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for various diseases. The measurement of CD34+ cells is crucial to schedule the peripheral blood stem cell collection and assess the engraftment potential of the apheresis product. The AQUIOS STEM system has been introduced as a novel application on the AQUIOS CL, a fully automated flow cytometer, for the enumeration of CD34+ hematopoietic progenitor cells (HPCs) in accordance with the The International Society for Hematotherapy and Graft Engineering guidelines. This study aimed to assess the potential of the novel AQUIOS STEM system versus currently used systems including the FACSCanto-II and the FACS Lyric flow cytometer in a multicenter study.
Methods
A total of 91 samples were used for the validation of the AQUOIS STEM system, including an analytical performance evaluation by means of assessing precision, sample stability, intersample carryover, and linearity and a method comparison with the present FACS systems in use to assess analytical and clinical decision agreement.
Results
Results showed excellent precision, with coefficient of variations <15% for dedicated quality control material and patient samples. There was no significant carry over. The fresh apheresis samples were stable when stored overnight at room temperature and at 4°C. Analytical comparison with the current systems demonstrated good correlation in peripheral blood, and minimal, clinically neglectable systematic and proportional bias in fresh apheresis products but a low correlation coefficient in cryopreserved products.
Conclusions
The STEM system on AQUIOS CL allows automated enumeration of CD34+ stem cells, demonstrating good analytical performance and promising overall outcomes in peripheral blood and fresh apheresis products.
{"title":"Evaluation of AQUIOS STEM, a novel method for automated CD34+ stem cell enumeration using flow cytometry","authors":"Kim Callebaut, Eva Gijbels, Jonathan Vanbesien, Dries Deeren, Jan Van Droogenbroeck, Jan Emmerechts, Elisabeth Moreau","doi":"10.1111/ijlh.14253","DOIUrl":"10.1111/ijlh.14253","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for various diseases. The measurement of CD34+ cells is crucial to schedule the peripheral blood stem cell collection and assess the engraftment potential of the apheresis product. The AQUIOS STEM system has been introduced as a novel application on the AQUIOS CL, a fully automated flow cytometer, for the enumeration of CD34+ hematopoietic progenitor cells (HPCs) in accordance with the The International Society for Hematotherapy and Graft Engineering guidelines. This study aimed to assess the potential of the novel AQUIOS STEM system versus currently used systems including the FACSCanto-II and the FACS Lyric flow cytometer in a multicenter study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 91 samples were used for the validation of the AQUOIS STEM system, including an analytical performance evaluation by means of assessing precision, sample stability, intersample carryover, and linearity and a method comparison with the present FACS systems in use to assess analytical and clinical decision agreement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Results showed excellent precision, with coefficient of variations <15% for dedicated quality control material and patient samples. There was no significant carry over. The fresh apheresis samples were stable when stored overnight at room temperature and at 4°C. Analytical comparison with the current systems demonstrated good correlation in peripheral blood, and minimal, clinically neglectable systematic and proportional bias in fresh apheresis products but a low correlation coefficient in cryopreserved products.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The STEM system on AQUIOS CL allows automated enumeration of CD34+ stem cells, demonstrating good analytical performance and promising overall outcomes in peripheral blood and fresh apheresis products.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139992185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Blood smear invaders: About a fatal case of bacteremia","authors":"Aurélien Bauduin, Marine Demoy, Franck Genevieve, Marie Tuffigo, Damien Luque Paz, Agathe Boussaroque","doi":"10.1111/ijlh.14256","DOIUrl":"10.1111/ijlh.14256","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cornelis L. Harteveld, Richard McCafferty, Terry Fawcett, Wendy N. Erber, International Council for the Standardization of Haematology (ICSH)
{"title":"International Council for Standardization in Haematology technical report 2023: Renewal of the reference material for haemiglobincyanide 19-1-B308 for use in standardization of blood haemoglobin measurements","authors":"Cornelis L. Harteveld, Richard McCafferty, Terry Fawcett, Wendy N. Erber, International Council for the Standardization of Haematology (ICSH)","doi":"10.1111/ijlh.14254","DOIUrl":"10.1111/ijlh.14254","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14254","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marcello Viscovo, Mia de Laurent Clemmensen, Federica Fosso, Elena Maiolo, Francesco Autore, Luca Laurenti, Stefan Hohaus, Patrizia Chiusolo
Introduction
Agarose gel-based conventional and real-time allele-specific polymerase chain reaction (AS-PCR) assays are currently used for sensitive detection and quantification of MYD88 L265P mutation. Visual inspection of an agarose gel can often be ambiguous. We propose a new allele-specific quantification PCR (AS-qPCR) assay, PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay, that uses Intercalating Nucleic Acid (INA®) technology for increased affinity and specificity.
Methods
This study compares PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay with conventional AS-PCR. We included a total of 102 peripheral and bone marrow blood samples from 94 patients with a lymphoproliferative disorder. Droplet digital PCR (ddPCR) was used as a third method in case of discrepancy.
Results
A positive percent agreement of 100% (95% CI 0.92–1.0) and a negative percent agreement of 98% (95% CI 0.90–1.0) were found between the conventional AS-PCR and the AS-qPCR methods. Including the ddPCR results to validate the discrepant cases, the sensitivity and specificity of PlentiPlex™ MYD88 Waldenström lymphoma qPCR Assay were 1.0 (95% CI 0.97–1.0) and 1.0 (95% CI 0.96–1.0), respectively.
Conclusion
Our data demonstrate that PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay is a fast, highly sensitive, and specific method for the detection of MYD88 L265P compared with conventional AS-PCR.
{"title":"PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation","authors":"Marcello Viscovo, Mia de Laurent Clemmensen, Federica Fosso, Elena Maiolo, Francesco Autore, Luca Laurenti, Stefan Hohaus, Patrizia Chiusolo","doi":"10.1111/ijlh.14255","DOIUrl":"10.1111/ijlh.14255","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Agarose gel-based conventional and real-time allele-specific polymerase chain reaction (AS-PCR) assays are currently used for sensitive detection and quantification of <i>MYD88</i> L265P mutation. Visual inspection of an agarose gel can often be ambiguous. We propose a new allele-specific quantification PCR (AS-qPCR) assay, PlentiPlex™ <i>MYD</i>88 Waldenström lymphoma qPCR assay, that uses Intercalating Nucleic Acid (INA®) technology for increased affinity and specificity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study compares PlentiPlex™ <i>MYD</i>88 Waldenström lymphoma qPCR assay with conventional AS-PCR. We included a total of 102 peripheral and bone marrow blood samples from 94 patients with a lymphoproliferative disorder. Droplet digital PCR (ddPCR) was used as a third method in case of discrepancy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A positive percent agreement of 100% (95% CI 0.92–1.0) and a negative percent agreement of 98% (95% CI 0.90–1.0) were found between the conventional AS-PCR and the AS-qPCR methods. Including the ddPCR results to validate the discrepant cases, the sensitivity and specificity of PlentiPlex™ <i>MYD</i>88 Waldenström lymphoma qPCR Assay were 1.0 (95% CI 0.97–1.0) and 1.0 (95% CI 0.96–1.0), respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our data demonstrate that PlentiPlex™ <i>MYD</i>88 Waldenström lymphoma qPCR assay is a fast, highly sensitive, and specific method for the detection of <i>MYD</i>88 L265P compared with conventional AS-PCR.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139934731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clot based assays used for lupus anticoagulant (LAC) detection are typically interpreted in a qualitative fashion and may not reflect LAC potency. In this cross-sectional study, we describe a method for quantifying the LAC titer using serial (dependent) two-fold dilutions in normal pooled plasma.
Methods
Serial dilutions of 51 residual plasma samples from 50 patients were tested using the Russell's viper venom screening time (DRVVT) and activated partial thromboplastin screening time (APTT) methodologies. The measured clotting times and the corresponding dilution factors were then used to derive a four-parameter logistic model. The LAC titer for each patient was interpolated as the sample dilution that corresponds to the upper reference interval limit of the corresponding assay.
Results
Calculated APTT and DRVVT LAC titers displayed a strong linear correlation (R2 = 0.84) between each other, but not with the degree of prolongation of the APTT/DRVVT screening time in the neat undiluted samples. Using data driven partitioning, patients could be grouped into low (<10) or high (≥10) DRVVT LAC titer. There were no significant differences in anticardiolipin (aCL) or anti-beta 2 glycoprotein 1 (aB2GPI) antibody levels or prevalence of thromboembolic events between low and high LAC titer groups. In contrast, antiphosphatidylserine/prothrombin (aPS/PT) IgM antibody levels, but not IgG, were significantly higher in the high LAC titer group.
Conclusions
The degree of prolongation of the APTT/DRVVT screening time is not correlated with the LAC titer. Only aPS/PT IgM antibodies levels were strongly correlated with the LAC titers. Additional studies are warranted to determine clinical implications of high LAC titers.
{"title":"The lupus anticoagulant titer is associated with elevated antiphosphatidylserine/prothrombin immunoglobulin-M isotype antibody levels","authors":"Abdulrahman Saadalla, Dong Chen, Melissa Stuart, Rajiv Pruthi, Nahla Heikal, Melissa Snyder, Aneel Ashrani, Jansen Seheult","doi":"10.1111/ijlh.14251","DOIUrl":"10.1111/ijlh.14251","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Clot based assays used for lupus anticoagulant (LAC) detection are typically interpreted in a qualitative fashion and may not reflect LAC potency. In this cross-sectional study, we describe a method for quantifying the LAC titer using serial (dependent) two-fold dilutions in normal pooled plasma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Serial dilutions of 51 residual plasma samples from 50 patients were tested using the Russell's viper venom screening time (DRVVT) and activated partial thromboplastin screening time (APTT) methodologies. The measured clotting times and the corresponding dilution factors were then used to derive a four-parameter logistic model. The LAC titer for each patient was interpolated as the sample dilution that corresponds to the upper reference interval limit of the corresponding assay.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Calculated APTT and DRVVT LAC titers displayed a strong linear correlation (<i>R</i><sup>2</sup> = 0.84) between each other, but not with the degree of prolongation of the APTT/DRVVT screening time in the neat undiluted samples. Using data driven partitioning, patients could be grouped into low (<10) or high (≥10) DRVVT LAC titer. There were no significant differences in anticardiolipin (aCL) or anti-beta 2 glycoprotein 1 (aB2GPI) antibody levels or prevalence of thromboembolic events between low and high LAC titer groups. In contrast, antiphosphatidylserine/prothrombin (aPS/PT) IgM antibody levels, but not IgG, were significantly higher in the high LAC titer group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The degree of prolongation of the APTT/DRVVT screening time is not correlated with the LAC titer. Only aPS/PT IgM antibodies levels were strongly correlated with the LAC titers. Additional studies are warranted to determine clinical implications of high LAC titers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139914275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas I. Mincherton, Stephanie J. Lam, Sarah E. Clarke, Henry Y. L. Hui, Jacques A. J. Malherbe, Hun S. Chuah, M. Hasib Sidiqi, Kathy A. Fuller, Wendy N. Erber
Background
Detection of del(17p) in myeloma is generally performed by fluorescence in situ hybridization (FISH) on a slide with analysis of up to 200 nuclei. The small cell sample analyzed makes this a low precision test. We report the utility of an automated FISH method, called “immuno-flowFISH”, to detect plasma cells with adverse prognostic risk del(17p) in bone marrow and blood samples of patients with myeloma.
Methods
Bone marrow (n = 31) and blood (n = 19) samples from 35 patients with myeloma were analyzed using immuno-flowFISH. Plasma cells were identified by CD38/CD138-immunophenotypic gating and assessed for the 17p locus and centromere of chromosome 17. Cells were acquired on an AMNIS ImageStreamX MkII imaging flow cytometer using INSPIRE software.
Results
Chromosome 17 abnormalities were identified in CD38/CD138-positive cells in bone marrow (6/31) and blood (4/19) samples when the percent plasma cell burden ranged from 0.03% to 100% of cells. Abnormalities could be identified in 14.5%–100% of plasma cells.
Conclusions
The “immuno-flowFISH” imaging flow cytometric method could detect del(17p) in plasma cells in both bone marrow and blood samples of myeloma patients. This method was also able to detect gains and losses of chromosome 17, which are also of prognostic significance. The lowest levels of 0.009% (bone marrow) and 0.001% (blood) for chromosome 17 abnormalities was below the detection limit of current FISH method. This method offers potential as a new means of identifying these prognostically important chromosomal defects, even when only rare cells are present and for serial disease monitoring.
{"title":"Imaging flow cytometric detection of del(17p) in bone marrow and circulating plasma cells in multiple myeloma","authors":"Thomas I. Mincherton, Stephanie J. Lam, Sarah E. Clarke, Henry Y. L. Hui, Jacques A. J. Malherbe, Hun S. Chuah, M. Hasib Sidiqi, Kathy A. Fuller, Wendy N. Erber","doi":"10.1111/ijlh.14248","DOIUrl":"10.1111/ijlh.14248","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Detection of del(17p) in myeloma is generally performed by fluorescence in situ hybridization (FISH) on a slide with analysis of up to 200 nuclei. The small cell sample analyzed makes this a low precision test. We report the utility of an automated FISH method, called “immuno-flowFISH”, to detect plasma cells with adverse prognostic risk del(17p) in bone marrow and blood samples of patients with myeloma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Bone marrow (<i>n</i> = 31) and blood (<i>n</i> = 19) samples from 35 patients with myeloma were analyzed using immuno-flowFISH. Plasma cells were identified by CD38/CD138-immunophenotypic gating and assessed for the 17p locus and centromere of chromosome 17. Cells were acquired on an AMNIS ImageStreamX MkII imaging flow cytometer using INSPIRE software.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Chromosome 17 abnormalities were identified in CD38/CD138-positive cells in bone marrow (6/31) and blood (4/19) samples when the percent plasma cell burden ranged from 0.03% to 100% of cells. Abnormalities could be identified in 14.5%–100% of plasma cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The “immuno-flowFISH” imaging flow cytometric method could detect del(17p) in plasma cells in both bone marrow and blood samples of myeloma patients. This method was also able to detect gains and losses of chromosome 17, which are also of prognostic significance. The lowest levels of 0.009% (bone marrow) and 0.001% (blood) for chromosome 17 abnormalities was below the detection limit of current FISH method. This method offers potential as a new means of identifying these prognostically important chromosomal defects, even when only rare cells are present and for serial disease monitoring.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14248","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139914274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Helbies Bedier, Jessica Theriault, David M. Conrad
{"title":"A circulating proplatelet identified in an iron-deficient patient","authors":"Helbies Bedier, Jessica Theriault, David M. Conrad","doi":"10.1111/ijlh.14247","DOIUrl":"10.1111/ijlh.14247","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139901087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antoine Leveque, Delphine Rolland, Marie-Pierre Ledoux, Célestine Simand, Alice Eischen, Caroline Mayeur-Rousse
A 65-year-old female patient with Burkitt lymphoma history in 2020 (currently in remission) was diagnosed with post-cytotoxic therapy acute myeloid leukemia (AML) in June 2023. The patient agreed to be included in ENHANCE-3, a double-blind randomized protocol designed to evaluate magrolimab safety and efficacy in combination with venetoclax and azacitidine in previously untreated AML patients ineligible for intensive therapy. Placebo or magrolimab were administrated in step-up doses for 2 weeks in association with usual doses of venetoclax and azacitidine, then gradual spaced. Magrolimab, a monoclonal anti-CD47 antibody, blocks the « don't eat me » signal from tumor cells to signal-regulatory protein alpha (SIRPα) positive immune cells.
For her hematological follow-up, complete blood count (CBC) were run on XN-9000 SYSMEX analyzer. A CBC interference was observed with red blood cell (RBC) agglutination from 2 to 10 h (H + 2 to H + 10) after the first placebo/magrolimab administration. Two RBC populations were identified on both optic and impedance channels: the usual RBC population, and an agglutinated one (Figure 1A,B). None of pre-analytic performed treatments (plasma substitution with saline solution, 37°C heating, citrate-based anticoagulation) corrected this interference. Therefore, none of the RBC parameters (except for hemoglobin level at 75 g/L) could be determined at H + 2 timepoint. Macroscopic and microscopic blood smear examinations confirmed RBC agglutination (Figure 1C–E). There was no biological evidence of hemolysis (haptoglobin, LDH, and bilirubin within normal ranges). Qualitative interferences resolved almost fully at H + 10 (Figure 1F–J). At that time, the hemoglobin level was 91 g/L and RBC parameters were acceptable only within the optic channel with RBC-optic at 2.77 Tera/L (T/L). Mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and mean corpuscular volume (MCV) were recalculated at 32.9 pg, 368 g/L and 89.4 fL, respectively. The same interference reoccurred after each magrolimab or placebo administration to a lesser extent and completely regressed within 24 h. However, a probable untrue decrease in hemoglobin level (−24 g/L) was only detected after the first administration.
Since CD47 is highly expressed by RBC, magrolimab early clinical trials have already highlighted RBC agglutinations during ABO blood typing.1, 2 Although this phenomena has never been reported for RBC parameters yet, we deduced the patient received magrolimab. Physicians should be aware of such interference, particularly in context of transfusion decision for AML patients, and repeat if necessary the CBC.
{"title":"Transient red blood cell agglutination after Magrolimab administration in acute myeloid leukemia","authors":"Antoine Leveque, Delphine Rolland, Marie-Pierre Ledoux, Célestine Simand, Alice Eischen, Caroline Mayeur-Rousse","doi":"10.1111/ijlh.14252","DOIUrl":"10.1111/ijlh.14252","url":null,"abstract":"<p>A 65-year-old female patient with Burkitt lymphoma history in 2020 (currently in remission) was diagnosed with post-cytotoxic therapy acute myeloid leukemia (AML) in June 2023. The patient agreed to be included in ENHANCE-3, a double-blind randomized protocol designed to evaluate magrolimab safety and efficacy in combination with venetoclax and azacitidine in previously untreated AML patients ineligible for intensive therapy. Placebo or magrolimab were administrated in step-up doses for 2 weeks in association with usual doses of venetoclax and azacitidine, then gradual spaced. Magrolimab, a monoclonal anti-CD47 antibody, blocks the « don't eat me » signal from tumor cells to signal-regulatory protein alpha (SIRPα) positive immune cells.</p><p>For her hematological follow-up, complete blood count (CBC) were run on XN-9000 SYSMEX analyzer. A CBC interference was observed with red blood cell (RBC) agglutination from 2 to 10 h (H + 2 to H + 10) after the first placebo/magrolimab administration. Two RBC populations were identified on both optic and impedance channels: the usual RBC population, and an agglutinated one (Figure 1A,B). None of pre-analytic performed treatments (plasma substitution with saline solution, 37°C heating, citrate-based anticoagulation) corrected this interference. Therefore, none of the RBC parameters (except for hemoglobin level at 75 g/L) could be determined at H + 2 timepoint. Macroscopic and microscopic blood smear examinations confirmed RBC agglutination (Figure 1C–E). There was no biological evidence of hemolysis (haptoglobin, LDH, and bilirubin within normal ranges). Qualitative interferences resolved almost fully at H + 10 (Figure 1F–J). At that time, the hemoglobin level was 91 g/L and RBC parameters were acceptable only within the optic channel with RBC-optic at 2.77 Tera/L (T/L). Mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and mean corpuscular volume (MCV) were recalculated at 32.9 pg, 368 g/L and 89.4 fL, respectively. The same interference reoccurred after each magrolimab or placebo administration to a lesser extent and completely regressed within 24 h. However, a probable untrue decrease in hemoglobin level (−24 g/L) was only detected after the first administration.</p><p>Since CD47 is highly expressed by RBC, magrolimab early clinical trials have already highlighted RBC agglutinations during ABO blood typing.<span><sup>1, 2</sup></span> Although this phenomena has never been reported for RBC parameters yet, we deduced the patient received magrolimab. Physicians should be aware of such interference, particularly in context of transfusion decision for AML patients, and repeat if necessary the CBC.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139747917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号